Madryn Asset Management has provided debt and equity financing intended to help Abbott-backed Bigfoot Biomedical bring its diabetes management technology to market.
Bigfoot Biomedical, a US-based diabetes management technology developer backed by medical device manufacturer Abbott, received $57m of debt and equity financing from alternative asset manager Madryn Asset Management on Wednesday.
Founded in 2014, Bigfoot is developing technology used to manage the dosage of insulin injections for people with type 1 and type 2 diabetes.
Products under development by the company include an insulin pen that can connect to smartphones and an automated infusion pump for insulin. The funding will go…
